Literature DB >> 21710841

High-dose interleukin-2 therapy for metastatic renal cell carcinoma and metastatic melanoma: still the standard.

Janice P Dutcher1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21710841

Source DB:  PubMed          Journal:  Oncology (Williston Park)        ISSN： 0890-9091            Impact factor:   2.990


× No keyword cloud information.
  3 in total

Review 1.  Antagonists of PD-1 and PD-L1 in Cancer Treatment.

Authors:  Evan J Lipson; Patrick M Forde; Hans-Joerg Hammers; Leisha A Emens; Janis M Taube; Suzanne L Topalian
Journal:  Semin Oncol       Date:  2015-06-10       Impact factor: 4.929

2.  A pilot study of paclitaxel combined with gemcitabine followed by interleukin-2 and granulocyte macrophage colony-stimulating factor for patients with metastatic melanoma.

Authors:  Rui-Qing Peng; Ya Ding; Xing Zhang; Yuan Liao; Li-Min Zheng; Xiao-Shi Zhang
Journal:  Cancer Biol Ther       Date:  2012-09-06       Impact factor: 4.742

3.  Radiotherapy and High-Dose Interleukin-2: Clinical and Immunological Results of a Proof of Principle Study in Metastatic Melanoma and Renal Cell Carcinoma.

Authors:  Jenny Bulgarelli; Claudia Piccinini; Elisabetta Petracci; Elena Pancisi; Anna Maria Granato; Francesco de Rosa; Massimo Guidoboni; Massimiliano Petrini; Valentina Ancarani; Giovanni Foschi; Antonino Romeo; Luca Tontini; Ugo De Giorgi; Cristian Lolli; Giorgia Gentili; Linda Valmorri; Alice Rossi; Fabio Ferroni; Carla Casadei; Pietro Cortesi; Laura Crudi; Laura Ridolfi
Journal:  Front Immunol       Date:  2021-10-27       Impact factor: 7.561
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.